Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
This article was originally published in PharmAsia News
Executive Summary
BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech
You may also be interested in...
WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
WuXiPharmaTech's biologics manufacturing site is expected to be fully operational in 2012.
WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
WuXiPharmaTech's biologics manufacturing site is expected to be fully operational in 2012.
WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year